A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.
about
Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.Giant cell arteritis: Current treatment and management.High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statinsRelapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patientsClinical use of biologics in vasculitis syndromes.Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up StudyPredictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis: A Prospective Longitudinal StudyCurrent understanding and management of giant cell arteritis and polymyalgia rheumatica.Acute-phase response in chronic urticaria.Clinical features of polymyalgia rheumatica and giant cell arteritis.Putative effects of potentially anti-angiogenic drugs in rheumatic diseases.Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease.Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept.Macrophages and angiogenesis in rheumatic diseases.Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis?Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis.Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis.Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanercept.Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.
P2860
Q34346251-49B4B59D-9254-40D7-86B9-22017EDCBD66Q35746677-9E37359B-D1EF-4323-BDF4-7C3FA4338CF6Q35782029-7D7A59F9-6927-4F08-9ABB-B973FBC32549Q36150929-7B61E833-ADB1-416D-84F3-EC85D6AE0159Q36358081-66C244F8-B631-470F-BDEF-FAE098ECC926Q36993376-3C896736-AB94-42C4-9A86-2AFA4CE01326Q37082033-A39A3928-1BDE-428B-A8AB-1764BE95D434Q37206621-F55808D0-0DA0-4F70-9CD2-6D7B1F2A208DQ37803414-4C4A48B0-C164-492C-BFBD-CF64B85359F2Q37961185-4B46B3D1-252D-4C00-A91F-AF97480AA514Q38028863-D7768589-9882-4E50-9D13-D22CA586D884Q38160325-1A8F3C06-0743-421D-B8AD-B398F01A0381Q38787301-852544B0-4E61-4913-944A-FDFDC35EEF6EQ38915556-9E5CFBE7-4172-4857-A6E4-1FFD6DD8FFC0Q40201731-F593CF9A-7C13-4926-81E6-B5262134B6E6Q41849684-DA33BAA3-EFBE-4BC3-BF7A-E80BCCF044A0Q42397614-F5B9A1D5-8698-475C-AC0F-230A66C9516DQ43035849-6E6E8A72-4C03-4BB9-8B3B-606A4AA2E70EQ45034871-C8009597-78CD-4A56-9CE9-EBBA643878C2Q46897584-9F781D18-5D9E-4347-A932-9732A8422324Q47104190-346A1EFF-97F7-47C7-8E1C-EA3BFD681F7C
P2860
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
A strong initial systemic infl ...... nts with giant-cell arteritis.
@ast
A strong initial systemic infl ...... nts with giant-cell arteritis.
@en
A strong initial systemic infl ...... nts with giant-cell arteritis.
@nl
type
label
A strong initial systemic infl ...... nts with giant-cell arteritis.
@ast
A strong initial systemic infl ...... nts with giant-cell arteritis.
@en
A strong initial systemic infl ...... nts with giant-cell arteritis.
@nl
prefLabel
A strong initial systemic infl ...... nts with giant-cell arteritis.
@ast
A strong initial systemic infl ...... nts with giant-cell arteritis.
@en
A strong initial systemic infl ...... nts with giant-cell arteritis.
@nl
P2093
P2860
P356
P1476
A strong initial systemic infl ...... nts with giant-cell arteritis.
@en
P2093
Alfonso López-Soto
Alvaro Urbano-Márquez
Ana García-Martínez
Joaquim Fernández-Solà
Jordi Casademont
Josep M Grau
José Hernández-Rodríguez
Maria C Cid
María-José Esteban
Xavier Filella
P2860
P356
10.1002/ART1.10161
P577
2002-02-01T00:00:00Z